LXRX (Lexicon Pharmaceuticals) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LXRX Lexicon Pharmaceuticals Inc LXRX
59 GF Score
Price $2.31
GF Value $8.43
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Lexicon Pharmaceuticals FFO per Share?

FFO per Share only applies to REITs.

LXRX
59GF Score
Lexicon Pharmaceuticals Inc LXRX
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lexicon Pharmaceuticals (LXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexicon Pharmaceuticals stock appears to be undervalued. The current stock price of $2.31 is trading 72.7% below its estimated GF Value™ of $8.43. GuruFocus considers Lexicon Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LXRX:

  • FFO per Share:
  • GF Value™: $8.43 vs. price of $2.31 (72.7% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the LXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lexicon Pharmaceuticals Business Description

Address 2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
59GF Score

Get the complete analysis for LXRX

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.31
Price
$8.43
GF Value